<DOC>
	<DOCNO>NCT01208766</DOCNO>
	<brief_summary>Study phase : phase III Study objective : - Comparison Bortezomib , Melphalan , Prednisone ( VMP ) High Dose Melphalan follow autologous stem cell transplantation ( ASCT ) - Comparison Bortezomib , Lenalidomide , Dexamethasone ( VRD ) consolidation versus consolidation - Comparison single versus tandem high dose Melphalan ASCT Patient population : Patients symptomatic multiple myeloma , previously untreated , ISS stag 1-3 , age 18-65 year inclusive Study design : Prospective , multicenter , intergroup , randomize Duration treatment : Expected duration induction , stem cell collection intensification 6 - 9 month . Consolidation VRD last 2 month Maintenance therapy Lenalidomide give relapse . All patient follow 10 year registration .</brief_summary>
	<brief_title>Study Compare VMP With HDM Followed VRD Consolidation Lenalidomide Maintenance Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients confirm diagnosis symptomatic multiple myeloma stage I III accord International Staging System ISS ( see appendix A ) , i.e . least one CRAB criterion present ; Measurable disease define presence Mprotein serum urine ( serum Mprotein &gt; 10 g/l urine Mprotein &gt; 200 mg/24 hour ) , abnormal free light chain ratio ; Age 1865 year inclusive ; WHO performance status 03 ( WHO=3 allow cause MM comorbid condition ) ; Negative pregnancy test inclusion applicable ; Written inform consent . Inclusion randomisation 1 : WHO performance 02 ; Bilirubin transaminases &lt; 2.5 time upper limit normal value ; A suitable stem cell graft contain least 4 x 106 CD34+ cells/kg ( accord national guideline ) . Inclusion randomisation 2 : Bilirubin transaminases &lt; 2.5 time upper limit normal value ; ANC &gt; = 0.5 x 109/l platelet &gt; 20 x 10^9/l ; Patient able adhere requirement Lenalidomide Pregnancy Prevention Risk Management Plan . Known intolerance Boron ; Systemic AL amyloidosis ; Primary Plasmacell Leukemia ; Nonsecretory MM ; Previous chemotherapy radiotherapy except local radiotherapy case local myeloma progression corticosteroid maximum 5 day symptom control ; Severe cardiac dysfunction ( NYHA classification IIIV ) ; Significant hepatic dysfunction , unless related myeloma ; Patients GFR &lt; 15 ml/min , Patients know HIVpositive ; Patients active , uncontrolled infection ; Patients neuropathy , CTC grade 2 high ; Patients history active malignancy past 5 year exception basal carcinoma skin stage 0 cervical carcinoma ; Patients willing capable use adequate contraception therapy ( men , premenopausal woman ) ; Lactating woman . Exclusion randomisation 1 : Severe pulmonary , neurologic , psychiatric disease ; CTCAE grade 34 polyneuropathy Bortezomib treatment ; Allogeneic Stem Cell Transplantation ( Allo SCT ) plan ; Progressive disease . ' Exclusion randomisation 2 : Progressive disease ; Neuropathy , except CTCAE grade 1 ; CTCAE grade 34 polyneuropathy Bortezomib treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Myeloma ( Kahler 's disease )</keyword>
</DOC>